Medical device strategy · Clinical evidence · Market access

The most expensive decisions in a device’s life are often made before the first patient..

Independent advice for medical device founders, boards and investors on clinical evidence, market access and commercial strategy, from first-in-human to exit.

Approval is one milestone; getting paid for, adopted and acquired are the others.

Planning a first-in-human or pivotal study? That’s the best time to talk.

FOUR EARLY DECISIONS

Clinical, access and commercial, planned together.

Clinical & device

The trial

Endpoints regulators, payers and clinicians accept

The device

Design choices that set the code and payment

Market & exit

The market

Where to launch, who pays, what centres can afford

The exit

What investors and acquirers need to see

Approved, paid for and adopted

The trial

Endpoints regulators, payers and clinicians accept

The device

Design choices that set the code and payment

The market

Where to launch, who pays, what centres can afford

The exit

What investors and acquirers need to see

Approved, paid for and adopted

Each is easiest to change before the first patient is treated. After approval, most are slow and expensive to revisit.

Clinical evidence

Trial design input on endpoints, comparators and sites, so one study answers regulators, payers and clinicians.

Market access

Coding, coverage and payment routes in the UK, Europe and the US, with a realistic timeline to first reimbursed sale.

US coding and payment strategy with AMA and CMS, and NICE and NHS England engagement in the UK.

Commercial strategy

Launch planning, market priorities and the evidence story investors and acquirers will want to see.

Launch planning, market priorities and the evidence story investors and acquirers will want to see..

Previous clients

  • Epiminder

    Nocionix

01

The problem

Approval is only half the journey.

New device procedures rarely fit existing codes or tariffs. Surgeons and centres won’t adopt a therapy that loses them money, and acquirers want to see both before they buy. Small design decisions matter more than most founders expect: something as simple as how a lead connects to the implant can change which code applies and roughly halve what the procedure pays. Found after approval, that’s slow and expensive to fix.

THE GAP BETWEEN APPROVAL AND ADOPTION

US

5.7 years

median time from FDA authorisation to any Medicare coverage for novel devices and diagnostics.¹

US

44%

of 64 novel technologies reached a Medicare coverage milestone during the study’s follow-up.¹

UK

17 years

estimated average time for a new device to go from successful clinical trial to mainstream NHS adoption.²

¹ Sexton ZA et al. JAMA Health Forum. 2023;4(8):e232260. Technologies authorised 2016–2019. ² NHS Improvement estimate, cited in the House of Commons, Westminster Hall debate on Innovation in the NHS, 3 March 2020.

After approval: the hurdles, by market

Each country values different things, and it all takes longer than you’d think.

Coding

AMA CPT

A new procedure needs the right code, and the evidence bar for each code category is different.

Coverage

CMS & payers

Coverage decisions turn on whether your trial answers the questions payers actually ask.

Payment

Facility economics

Physician and surgery-centre economics drive adoption. If they don’t make a reasonable margin, they won’t use it, however good the data.

02

Where to start

The two-minute readiness check

0 of 5 answered

Five questions every medical device board should be able to answer before the pivotal protocol is locked.

Answer all five questions below to see your result here.
  1. 1. Does your pivotal protocol collect health-economic and resource-use data?

  2. 2. Do you know which procedure code you will use in each target market?

  3. 3. Have you modelled hospital payment against your device and procedure cost?

  4. 4. Have payers, not just regulators, accepted endpoints like yours before?

  5. 5. Has your board seen a timeline from approval to first reimbursed sale?

Start with a Readiness Review.

Most of what I find in these reviews is cheap to fix before the protocol is locked. A year later, much of it can’t be fixed at all.

Where most clients start

Reimbursement Readiness Review

Reimbursement Readiness Review

I look at your protocol, device design, evidence plan, target markets and investor story, and tell you where things are likely to get stuck, whether with regulators, payers, clinicians or buyers, and what to change. You get a written report your board can act on.

Timing

Planned around your protocol deadline

Fee

Fixed, agreed up front

Markets

UK · EU · US

You leave with

Evidence-gap analysis of your pivotal protocol against what payers and clinicians will ask

Coding route for the UK and US, with the risks in each

Access plan and timeline from approval to first reimbursed sale

Strategic-fit view: what an investor or acquirer would want to see

Board and investor summary you can share as it is

See an example scorecard from a review

Need more than a review? Some clients keep me on afterwards for ongoing access support, scoped and agreed with you.

Limited availability. I take a small number of engagements alongside my current role, and never with directly competing technologies.

Specialist input. If a project needs health economics or regulatory expertise, I’ll tell you and can introduce people I trust.

03

For investors and acquirers

What I’d want to know before investing.

A therapy can have strong clinical data and still struggle to be paid for, adopted or bought. The gap most often missed is the economics of whoever pays: if the clinician, hospital or clinic can’t make a reasonable margin from using it, or patients won’t pay for it themselves, it won’t be adopted, however good the data. I offer a practical, independent view of a therapy’s evidence, payment and adoption path, alongside your formal diligence.

Questions I can help you answer

Will the evidence hold up?

Whether the trial design and endpoints will satisfy payers and clinicians, not just regulators.

How long until it is actually paid for?

Coding, coverage and payment in the markets that matter, and whether the plan’s timing is realistic.

Will doctors and centres adopt it?

Who uses it, how it fits their day, and whether the economics work for the clinician and the site of care..

How it works: most investors start with a one-hour call about a specific company. If that’s useful, we can agree a short written view or help on particular questions.

Confidential and conflict-checked. I’m happy to sign an NDA before we talk, and I don’t advise on companies with competing technologies or connected to my current employer.

04

Experience

Situations you might recognise.

Every company is different, but most of these will sound familiar.

CLINICAL EVIDENCE

Designing a pivotal trial

Shaping endpoints, sites and budget so the data answers payers and clinicians as well as regulators.


Implantable neuromodulation · US and EU.

MARKET ACCESS

CLINICAL EVIDENCE

No code that fits the procedure

Designing a pivotal trial

SWorking out the coding route, facility economics and the case for a new code, with AMA and CMS engagement.


Shaping endpoints, sites and budget so the data answers payers and clinicians as well as regulators.



Breakthrough-designated implant · US

MARKET ACCESS

No code that fits the procedure

Working out the coding route, facility economics and the case for a new code, with AMA and CMS engagement.


Breakthrough-designated implant · US

MARKET ACCESS

Entering the UK

NICE, NHS England and clinical relationships for companies without a UK presence..



Implantable, wearable and diagnostic devices · UK

COMMERCIAL STRATEGY

Deciding where to launch

Assessing European markets so a board could decide whether, and when, to pursue CE approval.


Assessing European markets so a board could decide whether, and when, to pursue CE approval.



Non-Invasive Nerve Stimulation · EU.

COMMERCIAL STRATEGY

Launching with no reimbursement route

Building markets country by country, setting up distribution, and working with clinicians, payers and patient groups.


Implantable headache therapy ·Nordics, Spain, Ialty

COMMERCIAL STRATEGY

Preparing for investors or a buyer

SBoard papers, valuation work, investor materials and partner discussions, through to a company sale.


SBoard papers, valuation work, investor materials and partner discussions, through to a company sale.



Early-stage neuromodulation · US and EU.

MARKET ACCESS

Entering the UK

NICE, NHS England and clinical relationships for companies without a UK presence.





Implantable, wearable and diagnostic devices · UK

Patients often have more influence on funding than companies expect.

Patients often have more influence on funding than companies expect.

Patients often have more influence on funding than companies expect.

Advocates and patient groups carry real weight with payers. In my experience they’re one of the most underused voices in market access.

Advocates and patient groups carry real weight with payers. In my experience they’re one of the most underused voices in market access.

05

What clients say

“

Among his outstanding merits are his deep knowledge of the UK reimbursement pathways and NICE, and his ability to forge lasting relationships with KOLs.

Among his outstanding merits are his deep knowledge of the UK reimbursement pathways and NICE, and his ability to forge lasting relationships with KOLs.

Among his outstanding merits are his deep knowledge of the UK reimbursement pathways and NICE, and his ability to forge lasting relationships with KOLs.

Founder, PD Neurotechnology

“Mercian Medical investigated the EU market in a way that helped shape our decision to pursue CE approval. We now have a clear understanding of what needs to be achieved and when.”

Former CEO, Spark Biomedical

“The key to access and reimbursement is knowing not only the processes but also the stakeholders. Mercian Medical's network has been key to us starting to build a presence and awareness that will prove invaluable as we further expand our therapy..”

Former COO, Nalu Medical

Latest thinking · November 2026

Five pivotal-trial decisions that quietly kill reimbursement

Five pivotal-trial decisions that quietly kill reimbursement

A short guide for medical device founders and boards, to share before your protocol is locked.

06

About

Started in the NHS. Grew neuromodulation businesses. Led a start-up to acquisition.

I started as a cardiac technician in the NHS, moved into device sales and clinical research, and spent two decades building medical device businesses, from UK P&L leadership at St. Jude Medical to opening new European markets for an emerging therapy. Most of my career has been in cardiology and neuromodulation, but the same principles apply across novel implantable medical devices.

I set up Mercian Medical in 2018 to advise companies without a UK presence. Since then I’ve led a headache device start-up through to its acquisition, and now lead commercialisation at MAN & SCIENCE, covering US market access, trial strategy and investor discussions. The work has since moved towards what I enjoy most: early-stage companies around first-in-human, when a simple decision can change where they are three to five years later. At events like LSX Europe I’m still struck by how little many founders have been told about reimbursement, coding and adoption. That’s the gap I try to fill.

Education & credentials

BMedSci (Hons), University of Birmingham

PgCert Neuromodulation & Pain Management, Queen Mary (2024)

EEPIN, City University London

Professional Diploma in Marketing, CIM

ICH GCP E6(R3) · ISO 14155:2020

Career

1995

Cardiac Technician

City Hospital NHS Trust

2000

Sales & Clinical Research

Biotronik UK and Medtronic

2008

BU Manager, Neuromodulation

St. Jude Medical UK

2014

Senior Regional Sales Director

Autonomic Technologies

2018

Founded Mercian Medical

Independent consultancy

2021

CEO, Palion Medical

Acquired by MAN & SCIENCE

Now

Global Head, Marketing & Commercialisation

MAN & SCIENCE

07

Questions

What founders and investors ask first.

Do you only work on reimbursement?

Do you only work with implants or neuromodulation?

We’re pre-first-in-human. Is it too early?

We’re already approved. Is it too late?

What does a Readiness Review cost?

What do you need from us to get started?

How quickly can you start?

Can you help on a live deal?

How do you handle confidentiality and conflicts?

Can you help with health economics or regulatory submissions?

How do you fit this around your current role?

Where are you based, and do you travel?

Developing, launching or investing in a new medical device?

Developing, launching or investing in a new medical device?

Developing, launching or investing in a new medical device?

Whether you’re planning a first study, approved but not yet paid for, or looking at an investment, tell me where you are and what you’re working on. If I can help, I’ll say how. If I can’t, I’ll try to point you to someone who can.

Tell me where you are

Name

Email